The Longevity Fund

Laura Deming, the founder and General Partner, leads all investment decisions. Deming has been singularly focused on the biology of aging since her teenage years, working in Cynthia Kenyon's lab and attending the Thiel Fellowship before launching the firm at 18. She combines scientific evaluation with a long-duration capital approach that reflects her personal conviction in longevity science.

It is a traditional venture capital firm with a concentrated, thesis-specific mandate. The Longevity Fund makes early-stage equity investments in private biotech companies, using standard fund structures. Its operational model is lean, built around Deming's general partnership and a scientific advisory network rather than a large investment team.

The firm's known portfolio companies are based in the United States, and its primary investment geography is North America. Deming has evaluated global longevity opportunities through her broader scientific network, but no international portfolio companies have been publicly disclosed.

The firm targets seed and Series A rounds, with a focus on platform biotechnology companies that require extended development timelines. Deming has stated publicly that aging science demands capital patience measured in decades, which shapes the fund's preference for early entry at valuations where long holding periods are structurally feasible.

The firm explicitly avoids general healthcare, late-stage biotech, and companies targeting individual age-related diseases without engaging the underlying biology of aging. Its mandate excludes digital health apps, healthcare services, and therapeutic approaches that do not address what Deming defines as the core mechanisms of the aging process.